Kezar Life Sciences announces positive top-line results from the Phase 2 MISSION study evaluating zetomipzomib for the treatment of patients with lupus nephritis

11 of 17 patients (64.7%) achieves a general renal response 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months Six of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less, at 6 months Zetomipzomib continues to show a favorable safety and tolerability profile when … Read more

FDA Approves Alopecia Drug That Restores Hair Growth in Many Patients

The disease can vary in severity, but for some it can be life-changing – a complete loss of body hair, including eyelashes and eyebrows, even nose hair and hair in the ears. And until recently, there was no treatment available for people with alopecia areata to regrow hair. But on Monday, the Food and Drug … Read more

Cogent Biosciences announces positive initial clinical data from the ongoing Phase 2 APEX study evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).

Cogent Biosciences, Inc. All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89% regardless of prior treatment with the KIT-D816V inhibitor All patients who underwent bone marrow biopsy scored ≥50% reduction in bone marrow mast cells and reduction in allelic fraction of variant KIT D816V in blood (VAF) … Read more